🇺🇸 FDA
Pipeline program

CD19 CAR T-Cell(CAT19T2)

2022-KY-094

Phase 2 mab terminated

Quick answer

CD19 CAR T-Cell(CAT19T2) for B-cell Acute Lymphoblastic Leukemia is a Phase 2 program (mab) at Zhujiang Hospital with 1 ClinicalTrials.gov record(s).

Program details

Company
Zhujiang Hospital
Indication
B-cell Acute Lymphoblastic Leukemia
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials